FDA grants priority review status to Gilead's hepatitis C drug

(Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir.

The FDA grants priority reviews to medicines that are considered potentially significant therapeutic advancements over existing therapies.

The FDA set a review date of December 8 for the drug, Gilead said.

Gilead's oral drug is considered the most advanced and high-profile of treatments free of interferon, a standard hepatitis C drug which has side effects including colds and muscle fatigue.

Drugmakers AbbVie and Bristol-Myers Squibb are also developing such treatments but they require patient to take more pills each day than Gilead's treatment.

(Reporting By Vrinda Manocha in Bangalore; Editing by Don Sebastian)

Source: http://news.yahoo.com/fda-grants-priority-review-status-gileads-hepatitis-c-220927469.html

country music awards autism awareness angelman syndrome total recall troy tulowitzki katie couric good morning america the rock vs john cena